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We analyzed the allelic and genotypic frequencies of the glu-
tathione-S-transferase P1 (GSTP1) rs1695 single nucleotide
polymorphism (SNP) in 290 patients with multiple sclerosis
(MS) and in 310 healthy controls. We found no significant
association between the rs1695 variant and MS. Among MS
patients, there was no relationship between the rs1695 variant
and either gender, clinical type of MS or the age of onset of MS.
These results suggest that the GSTP1 rs1695 polymorphism is
not a risk factor for MS.
Genome-wide association studies in samples from MS
patients have identified more than 100 loci with genome-wide
significance, but most of these loci had a modest odds ratio
(OR) in the range of 1.1–1.3; only HLA (especially the HLA-
DRB1*15:01 haplotype) had a strong association with MS risk.1
A possible role for oxidative stress and lipid peroxidation in the
pathogenesis of MS has been suggested by the presence of oxi-
dative stress markers in the spinal cord, brain, and cerebrosp-
inal fluid of MS patients and in experimental autoimmune
encephalomyelitis (reviewed in Ref. 1).
Glutathione S-transferases (GSTs) are a superfamily of
dimeric phase 2 metabolic enzymes that catalyze the conjugation
of reduced glutathione with electrophilic groups of carcinogens,
herbicides/pesticides, and other compounds. GSTP1 also plays a
role in inflammatory processes (http://www.ncbi.nlm.nih.gov/
pubmed/23596995). In humans, the GSTs are divided into a
number of major classes that have distinct substrate specificities
and tissue distributions. Polymorphisms in the GSTM1, GSTP1
and GSTT1 genes are known to alter gene function. The rs1695
variant of the GSTP1 gene (chromosome 11q13; Gene identity
2950, MIM 134660; http://www.ncbi.nlm.nih.gov/gene/2950)
causes an amino-acid substitution and reduces the catalytic
activity of the enzyme (http://www.ncbi.nlm.nih.gov/pubmed/
9600848, http://www.ncbi.nlm.nih.gov/pubmed/16488119 and
http://www.ncbi.nlm.nih.gov/pubmed/22401947). The rs1695
variant is the only non-synonymous polymorphism of the
GSTP1 gene with a significant allele frequency in human popu-
lations and minor allele frequencies ranging from 17% to 44%
(http://browser.1000genomes.org/Homo_sapiens/Variation/
Population?db5core;r511:67352189-67353189;v5rs1695;vdb
5variation;vf521985). The frequency of the GSTP1 rs1695
variant is nearly 35% in the Spanish population.2
Although GSTP1 polymorphisms were not identified as pos-
sible susceptibility genes by genome-wide association studies,
we explored a possible relationship between GSTP1 polymor-
phisms and allelic gene variants and the risk of MS due to the
possible role of oxidative stress and lipid peroxidation in the
pathogenesis of MS1 and the upregulation of GSTP1 gene ex-
pression found in active demyelinating MS lesions.3 Although
two preliminary studies did not find a relationship between
polymorphisms in either GSTM14,5 or GSTT15 and the risk
for MS, another recent study showed an association between
GSTT1 deletion and MS susceptibility6. Another study repor-
ted a relationship between GSTM1, GSTM3 and GSTP1, but
not GSTT1, and the degree of disability in MS.7
Alexoudi et al.8 reported a similar distribution of GSTP1
genotypes in MS patients and controls but a higher frequency
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of GSTP1 heterozygotes in patients with relapsing–remitting
MS. This was particularly evident for the benign forms of
relapsing–remitting MS. These authors also found a signifi-
cantly higher frequency of GSTP1 heterozygotes and
NAD(P)H dehydrogenase, quinone 1 (NQO1) variant genotypes
in MS patients compared with controls, suggesting that an
interaction between these two genes might contribute to the
risk of MS.
We examined the frequency of the rs1695 SNP in the GSTP1
gene of 290 unselected and unrelated Caucasian Spanish
patients with no other previous neurological diseases who
fulfilled the McDonald’s criteria for definite MS9 (90 men
and 200 women, mean age: 43.76611.32 years, mean age at
onset 32.64610.57 years; mean Expanded Disability Score
Scale53.2762.44; 155 relapsing–remitting MS, 92 secondary
progressive MS and 43 primary progressive MS), and in 310
healthy unrelated Caucasian Spanish individuals who were
gender- and age-matched with the MS cases (97 men and 213
women; mean age: 43.74612.2 years). The subject recruitment
details are described elsewhere1.
All of the participants who were included in the study pro-
vided written informed consent. The study protocol was ap-
proved by the Ethics Committees of the University Hospitals
‘Prı´ncipe de Asturias’ and ‘Infanta Cristina’ (Badajoz). The
study was conducted according to the principles expressed in
the declaration of Helsinki. Most of the patients in this study
had participated in previous genetic association studies for the
risk of MS.1
Table 1 GSTP1 rs1695 genotype and allelic variants of patients with multiple sclerosis (MS) and healthy volunteers
Genotype A/A Genotype A/G Genotype G/G Allele A Allele G
All MS patients (N5290),
no. (%) (95% CI)
140 (48.3; 42.5–54.0) 122 (42.1; 36.4–47.8) 28 (9.7; 6.3–13.1) 402 (69.3; 65.6–73.1) 178 (30.7; 26.9–34.4)
Controls (N5310),
no. (%) (95% CI)
151 (48.7; 43.1–54.3) 127 (41.0; 35.5–46.4) 32 (10.3; 6.9–13.7) 429 (69.2; 65.6–72.8) 191 (30.8; 27.2–34.4)
Intergroup comparison
values, OR (95% CI); P
0.98 (0.70–1.37);
0.915
1.05 (0.75–1.47);
0.785
0.93 (0.53–1.64);
0.786
1.00 (0.78–1.30);
0.965
1.00 (0.77–1.29);
0.965
Negative predictive
value (95% CI)
0.52 (0.47–0.56) 0.52 (0.49–0.56) 0.52 (0.50–0.53) 0.52 (0.47–0.56) 0.52 (0.50–0.54)
Men MS patients (N590),
no. (%) (95% CI)
38 (42.2; 32.0–52.4) 42 (46.7; 36.4–57.0) 10 (11.1; 4.6–17.6) 118 (65.6; 58.6–72.5) 62 (34.4; 27.5–41.4)
Men controls (N597),
no. (%) (95% CI)
47 (48.5; 38.5–58.4) 39 (40.2; 30.4–50.0) 11 (11.3; 5.0–17.7) 133 (68.6; 62.0–75.1) 61 (31.4; 24.9–38.0)
Intergroup comparison
values, OR (95% CI); P
0.78 (0.42–1.44);
0.394
1.30 (0.70–2.42);
0.374
0.98 (0.36–2.64);
0.961
0.87 (0.55–1.38);
0.538
1.15 (0.73–1.81);
0.538
Negative predictive value (95% CI) 0.49 (0.42–0.56) 0.55 (0.48–0.61) 0.52 (0.49–0.55) 0.50 (0.42–0.57) 0.53 (0.49–0.57)
Women MS patients
(N5200), no. (%)
(95% CI)
102 (51.0; 44.1–57.9) 80 (40.0; 33.2–46.8) 18 (9.0; 5.0–13.0) 284 (71.0; 66.6–75.4) 116 (29.0; 24.6–33.4)
Women controls (N5213),
no. (%) (95% CI)
104 (48.8; 42.1–55.5) 88 (41.3; 34.7–47.9) 21 (9.9; 5.9–13.9) 296 (69.5; 65.1–73.9) 130 (30.5; 26.1–34.9)
Intergroup comparison
values, OR (95% CI); P
1.09 (0.73–1.64);
0.659
0.95 (0.63–1.43);
0.786
0.90 (0.44–1.84);
0.766
1.08 (0.79–1.47);
0.634
0.93 (0.68–1.27);
0.634
Negative predictive value (95% CI) 0.53 (0.48–0.58) 0.51 (0.47–0.55) 0.51 (0.50–0.53) 0.53 (0.47–0.58) 0.51 (0.49–0.53)
Relapsing–remitting MS
(N5155),
no. (%; 95% CI)
75 (48.4; 40.5–56.3) 64 (41.3; 33.5–49.0) 16 (10.3; 5.5–15.1) 214 (69.0; 63.9–74.2) 96 (31.0; 25.8–36.1)
Comparison values with
controls, OR (95% CI); P
0.99 (0.66–1.48);
0.948
0.85 (0.57–1.28);
0.417
1.00 (0.51–1.96);
1.00
0.99 (0.73–1.35);
0.960
1.01 (0.74–1.37);
0.960
Negative predictive value (95% CI) 0.66 (0.62–0.71) 0.67 (0.63–0.71) 0.67 (0.65–0.68) 0.67 (0.62–0.71) 0.67 (0.65–0.69)
Secondary progressive
MS (N592),
no. (%; 95% CI)
48 (52.2; 42.0–62.4) 34 (37.0; 27.1–46.8) 10 (10.9; 4.5–17.2) 130 (70.7; 64.1–77.2) 54 (29.3; 22.8–35.9)
Comparison values with
controls, OR (95% CI); P
1.15 (0.70–1.88);
0.560
0.71 (0.43–1.17);
0.158
1.06 (0.47–2.36);
0.880
1.07 (0.74–1.56);
0.706
0.93 (0.64–1.36);
0.706
Negative predictive value (95% CI) 0.78 (0.74–0.83) 0.76 (0.73–0.80) 0.77 (0.76–0.79) 0.78 (0.73–0.82) 0.77 (0.75–0.79)
Primary progressive MS
(N543), no. (%; 95% CI)
17 (39.5; 24.9–54.1) 24 (55.8; 41.0–70.7) 2 (4.7; 21.6–10.9) 58 (67.4; 57.5–77.3) 28 (32.6; 22.7–42.5)
Comparison values with
controls, OR (95% CI); P
0.69 (0.34–1.38);
0.260
1.53 (0.77–3.04);
0.190
0.42 (0.07–1.92);
0.238
0.99 (0.56–1.54);
0.742
1.08 (0.65–1.80);
0.742
Negative predictive value (95% CI) 0.86 (0.83–0.90)127 0.91 (0.87–0.94) 0.87 (0.87–0.89) 0.87 (0.83–0.91) 0.88 (0.87–0.90)
Abbreviations: CI, confidence interval; MS, multiple sclerosis; OR, odds ratio.
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The detection of the rs1695 allelic variant was performed on
genomic DNA isolated from venous blood samples from the
participants using TaqMan assays (C___3237198_20; Life
Technologies, Alcobendas, Madrid, Spain) designed to detect
the rs1695 SNP. The methodology is similar to that used to
detect other SNP allelic variants.1
Hardy–Weinberg equilibrium was analyzed using DeFinetti
software (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The allelic and
genotypic frequency analyses were performed using SPSS soft-
ware, ver. 17. International Business Machines Espan˜a, Santa
Hortensia 26–28, 28002 Madrid, SPAIN. The intergroup com-
parison values were calculated using either Chi-squared or
Fisher’s exact tests where appropriate. The 95% confidence
intervals were also calculated. The sample size was determined
using the allelic frequencies reported for South-European
Caucasian individuals as described elsewhere10 and a genetic
model analyzing the disease gene frequency of risk alleles with
an OR51.5 (P50.05) for bilateral and unilateral associations of
the risk with a variant allele of 94.48% and 97.21%, respectively.
The negative predictive value was calculated as d/r2 (d, the
number of control individuals with the risk factor absent; r2,
the sum of the patients and controls with the risk factor absent).
The comparisons between the ages of onset for the different
possible genotypes were performed using a Newman–Keuls test.
The frequencies of the GSTP1 rs1695 genotypic and allelic
variants in patients diagnosed with MS did not differ from
those of the controls, were in Hardy–Weinberg equilibrium
(Table 1) and were not influenced by gender (Table 1). The
mean age of onset of MS did not differ significantly between the
patients who were either homozygous for GSTP1 rs1695 (A/A,
mean6s.d.531.76610.54 years), heterozygous for GSTP1
rs1695 (A/G, mean6s.d.533.65611.23 years) or lacked
GSTP1 rs1695 (G/G, mean6s.d.532.3068.67 years).
The distribution of the GSTP1 rs1695 genotypes and the
allelic frequencies did not differ among the ‘relapsing–remit-
ting’, ‘primary progressive’ and ‘secondary progressive’ pheno-
types of MS or between each type and the controls (Table 1).
There were no significant differences between the MS
patients and the controls in the genotype distribution analysis
of combined GSTP1 rs1695 and NQO1 rs1800566 polymorph-
isms (data not shown).
The limitations of this study include the size of the cohorts
analyzed, which may not have been sufficient to confirm or
exclude a role for GSTP1 in MS. Although the sample size is
adequate to detect an OR as small as 1.5, more modest associa-
tions would not be detected. In addition, because this study
included patients with different severities of MS disease, it does
not allow for the investigation of the influence of the GSTP1
genotypes on the disability or severity of the disease. The
optimum design for this study would be a prospective design,
including genotyping patients with a recent diagnosis of MS
and re-examining the same patient cohort after long-term fol-
low-up had established the final disease type.
Taking into account the limitations of the present study, the
results suggest that the GSTP1 rs1695 genotypes and allelic
variants are not related to the risk for MS in Caucasian
Spanish people, the age of onset of MS or the clinical type of
MS. In addition, we found no evidence of an interaction
between the GSTP1 rs1695 and NQO1 rs1800566 variant gen-
otypes. The lack of an association between the GSTP1 rs1695
SNP and MS risk in this study does not exclude the possibility
that other SNPs in the GSTP1 gene could contribute to the risk
of developing MS.
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